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The length of female reproductive lifespan is associated with multiple adverse outcomes, including breast
cancer, cardiovascular disease and infertility. The biological processes that govern the timing of the beginning
and end of reproductive life are not well understood. Genetic variants are known to contribute to ∼50% of the
variation in both age at menarche and menopause, but to date the known genes explain <15% of the genetic com-
ponent. We have used genome-wide association in a bivariate meta-analysis of both traits to identify genes
involved in determining reproductive lifespan. We observed significant genetic correlation between the two
traits using genome-wide complex trait analysis. However, we found no robust statistical evidence for individual
variants with an effect on both traits. A novel association with age at menopause was detected for a variant
rs1800932 in the mismatch repair geneMSH6 (P 5 1.9 3 1029), which was also associated with altered expres-
sion levels ofMSH6mRNA in multiple tissues. This study contributes to the growing evidence that DNA repair
processes play a key role in ovarian ageing and could be an important therapeutic target for infertility.
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INTRODUCTION
Female reproductive lifespan starts just prior to menarche, the
onset of the first menstrual bleed and finishes when oocyte
supply becomes exhausted at menopause. Both processes are
governed by genetic and non-genetic factors and the timing of
these events is associated with multiple adverse health out-
comes, including breast cancer, cardiovascular disease, osteo-
porotic fractures and infertility (1). Recent genome-wide
association studies (GWAS) have identified 32 loci involved in
age at menarche (2) and 17 with age at natural menopause (3):
however none of the variants identified to date overlap. Epi-
demiological studies also do not strongly support a role for over-
lapping aetiology in the processes governing timing of menarche
and menopause (4–7). Age at menarche has decreased signifi-
cantly in recent history and this has been thought to be largely
due to increased levels of childhood obesity (8–10). The role
of adiposity in regulating menarche timing is supported by
genetic studies which have reported that many genes involved
in the regulation of fat mass are also associated with timing of
menarche (11–13). Secular changes in menopause age are
more controversial with individual studies reporting conflicting
findings (14,15). The correlation between ages at menopause and
menarche is also controversial, but larger studies show a modest
correlation between the two phenotypes (16) and as both events
involve the same organ system, it is conceivable that there are
common physiological processes involved, which may be influ-
enced by genetic and environmental factors.
The length of reproductive lifespan has been associated with
several adverse health outcomes, particularly breast cancer.
Genes involved in regulating reproductive lifespan in humans
have not been described to date. There are two ways in which
reproductive lifespan can be altered: either total length, or it
can be temporally shifted, either earlier or later. These shifts
in lifespan would not be detected if the outcome measured
was the length of reproductive lifespan. It is possible that
both menarche and menopause could occur early, yet the time
period between the two events could be normal. In order to
capture the features of this phenotype and investigate the under-
lying genetic aetiology, we used a bivariate GWAS method to
identify genetic loci associated with both age at menopause
and menarche in either direction. This study incorporated
GWAS data from the ReproGen consortium meta-analyses of
87 802 individuals for menarche and 38 968 individuals for
menopause (2,17).
RESULTS
Genetic correlation between traits
We performed a restricted maximum likelihood (REML) bivari-
ate analysis (18,19) within the Women’s Genome Health Study
(total sample N ¼ 21 505) to test for genome-wide genetic cor-
relation between timing of menarche and menopause. Using
329 966 autosomal SNPs we observed a positive correlation of
rgenetic ¼ 0.138 (P ¼ 0.04, s.e 0.068). This result remained
similar after adjustment for the top 10 principal components of
population stratification.
Bivariate meta-analysis
The bivariate meta-analysis for menarche and menopause
generated two signals with genome-wide significant P values
,5 × 1028 and a further four independent signals with P
values ,1 × 1027 (Table 1). We assessed the association with
each of the individual traits of the top bivariate signal plus
SNPs in linkage disequilibrium (LD) with the best SNP. Of the
six top hits, for four signals either the top SNP, or a SNP in LD
with the top SNP (hapmap r2. 0.05), had been previously iden-
tified in the GWAS for one of the traits individually. The stron-
gest bivariate signal was near GAB2, a known locus for menarche
(2) and SNPs near FSHB, SYCP2L and PRRC2A were known
loci for menopause (3). There were two signals near RPAIN
and MSH6, which had not been previously reported for either
trait and had P values of 1 × 1027 and 3 × 1027, respectively
in the bivariate analysis. We did not have sufficiently robust stat-
istical evidence for any locus being associated with both meno-
pause and menarche and thus influencing reproductive lifespan.
An ingenuity pathway analysis of the top six signals
(www.ingenuity.com) found an enrichment in the ovarian
cancer signalling pathway (P ¼ 7.67 × 1024), with three of
the six genes closest to the top variants being in that pathway
(FSHB, GAB2 and MSH6).
Replication of top signals in individual traits
In order to increase our power to detect SNPs associated with
both traits, we increased our sample size for the top six loci.
We tested the top 6 signals in additional in silico replication
cohorts, including up to 28 470 individuals from 22 studies for
menarche and up to 19 851 individuals from 22 studies for
Table 1. Results of bivariate analysis
Region Gene SNP Known region? r2 with known
GWAS SNP
Ref allele Bivariate, P-value Effect on reproductive
lifespan
11q14.1 GAB2 rs11603112 Menarche (2) 0.82 A 4.13 × 10210 Right shift
11p14.1 FSHB rs11031002 Menopause (3) 0.76 A 1.63 × 10209 Right shift
6p24.2 SYCP2L rs9467921 Menopause (3) 0.08 C 9.82 × 10208 Lifespan increase
6p21.32 PRRC2A rs2471980 Menopause (3) 0.45 C 1.17 × 10207 Left shift
17p13.2 RPAIN rs4790770 – – A 1.24 × 10207 Lifespan decrease
2p16.3 MSH6 rs1800932 – – A 3.27 × 10207 Left shift
Effect on reproductive lifespan gives the effect directions for both menarche and menopause associations; right shift ¼ menarche increasing allele is menopause
increasing allele (and vice versa for left shift), reproductive lifespan increase ¼ menarche decreasing allele same as menopause increasing allele (vice versa for
reproductive lifespan decrease). Known regions are loci that have been identified in previous GWAS efforts for the individual traits.
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menopause (Table 2). One of the six bivariate SNPs from the dis-
covery analysis reached genome-wide significance in the com-
bined meta-analysis for menopause alone (rs1800932, P ¼
2 × 1029). This variant was in the MSH6 gene on chromosome
2 and was associated with a 1.3 months (se ¼ 0.38) reduction in
menopause age per common allele in the replication cohorts
alone (allele frequency ¼ 0.83) (Fig. 1).
Functional significanceofnovel variant forageatmenopause
We investigated the functional significance of the novel locus
associated with age at menopause by determining whether the
top variant, or SNPs in LD with it, were associated with expres-
sion levels of any genes in the genome. We accessed data from
four tissue types (monocytes, whole blood, liver and lung) and
in all tissues rs1800932 or rs3136247 (r2 ¼ 0.95) was associated
with expression of MSH6 (P ¼ 3.9 × 1026 –3.1 × 10220). In
monocytes, whole blood and liver, rs3136247 was the SNP
most strongly associated with expression of MSH6, but in lung
tissue the best SNP was rs2047681 (r2 ¼ 0.6 with rs3136247).
SNPs in LD with top bivariate signals
In addition to the top bivariate SNP, we chose to also replicate the
strongest SNP from each individual trait GWAS, which was in
LD (hapmap r2. 0.8) with the lead bivariate SNP (Table 2).
In the individual menarche GWAS five independent SNPs in
LD with a bivariate signal were more strongly associated with
menarche than the lead bivariate SNP. Following the replication
stage, none of the five SNPs reached genome-wide significance
in the combined analysis of discovery and replication data, but
statistical evidence increased for a known menopause locus in
PRRC2A being associated with age at menarche following
replication, with the P value strengthening from 2 × 1024 to
5 × 1025. In the univariate menopause GWAS five SNPs in
LD with top bivariate SNPs gave a stronger association and
were taken forward for replication, but the only SNPs that
gave a stronger association following replication were the
three previously known menopause signals.
DISCUSSION
Female reproductive lifespan starts at menarche and ends at
menopause and we therefore performed a bivariate analysis of
the two traits. Two signals reached genome-wide significance
in this analysis, but these were both heavily driven by low
P values in one of the individual traits. GAB2 is a known
signal for menarche and FSHB for menopause (2,3). We
sought to improve the statistical association for the second trait
by in silico replication, but for both variants the statistical
evidence got weaker. We also took four bivariate signals
forward for additional replication, which were just below the
genome-wide significance threshold, but none were robustly
associated in both traits. The most promising bivariate signal
after replication was associated with a left shift in reproductive
lifespan and was in the HLA III region on chromosome 6
(near PRRC2A gene), which is a known signal for menopause
and reached P ¼ 5 × 1025 for menarche, following replication.
This genomic region has also been associated with other T
a
b
le
2
.
F
o
ll
o
w
-u
p
o
f
to
p
si
x
b
iv
ar
ia
te
si
g
n
al
s
fo
r
as
so
ci
at
io
n
w
it
h
in
d
iv
id
u
al
tr
ai
ts
G
en
e
T
o
p
b
iv
ar
ia
te
S
N
P
M
en
ar
ch
e
(P
)
M
en
o
p
au
se
(P
)
T
o
p
M
en
ar
ch
e
S
N
P
in
re
g
io
n
T
o
p
M
en
o
p
au
se
S
N
P
in
re
g
io
n
S
N
P
r2
D
is
co
v
er
y
(P
)
R
ep
li
ca
ti
o
n
(P
)
C
o
m
b
in
ed
(P
)
N
S
N
P
r2
D
is
co
v
er
y
(P
)
R
ep
li
ca
ti
o
n
(P
)
C
o
m
b
in
ed
(P
)
N
G
A
B
2
rs
1
1
6
0
3
1
1
2
5
.7
9
E
–
1
0
1
.0
5
E
–
0
4
rs
1
0
8
9
9
4
8
9
0
.8
2
2
.4
1
E
–
1
0
0
.0
2
4
.6
2
E
2
1
1
1
1
6
2
6
8
rs
2
4
5
0
1
2
9
0
.8
4
4
.6
2
E
2
0
5
0
.1
5
1
.9
4
E
2
0
4
4
8
7
1
6
F
S
H
B
rs
1
1
0
3
1
0
0
2
4
.5
6
E
–
0
5
3
.5
2
E
2
0
8
rs
1
0
8
3
5
6
4
9
0
.7
1
8
.1
7
E
2
0
6
0
.7
1
3
.7
1
E
2
0
4
1
1
6
2
6
8
rs
1
2
2
9
4
1
0
4
0
.7
6
1
.6
3
E
2
0
8
1
.8
9
E
2
0
4
6
.1
6
E
2
1
1
4
8
7
1
7
S
Y
C
P
2
L
rs
9
4
6
7
9
2
1
2
.5
6
E
2
0
3
3
.9
3
E
2
0
7
rs
9
4
6
7
9
2
1
2
2
.5
6
E
-0
3
0
.8
8
8
.5
0
E
2
0
3
1
1
6
2
6
7
rs
2
1
5
3
1
5
7
0
.0
8
9
.4
0
E
2
1
1
0
.0
7
4
.0
2
E
2
1
1
4
8
7
1
5
P
R
R
C
2
A
rs
2
4
7
1
9
8
0
2
.2
0
E
-0
4
1
.1
8
E
2
0
6
rs
6
6
0
5
9
4
0
.1
3
1
.8
1
E
2
0
4
0
.1
1
5
.1
4
E
2
0
5
1
1
6
2
6
4
rs
1
0
4
6
0
8
9
0
.4
5
1
.3
1
E
2
1
3
2
.9
6
E
2
0
4
2
.5
9
E
2
1
4
4
8
7
0
8
R
P
A
IN
rs
4
7
9
0
7
7
0
7
.4
8
E
2
0
6
7
.7
9
E
2
0
5
rs
8
0
7
4
6
1
7
1
.0
0
7
.0
0
E
2
0
6
0
.6
0
4
.3
0
E
-0
5
1
1
6
2
6
6
rs
4
7
9
0
7
7
2
0
.8
8
8
.7
8
E
2
0
6
0
.1
5
6
.2
4
E
2
0
5
4
8
7
1
6
M
S
H
6
rs
1
8
0
0
9
3
2
4
.8
9
E
2
0
3
3
.3
5
E
2
0
7
rs
3
1
3
6
2
4
7
1
.0
0
4
.4
1
E
2
0
3
0
.6
0
3
.4
4
E
2
0
2
1
1
6
2
6
7
rs
1
8
0
0
9
3
2
2
3
.3
5
E
2
0
7
0
.0
0
0
4
1
.8
7
E
2
0
9
5
8
8
1
2
F
o
r
m
en
ar
ch
e
1
1
S
N
P
s
h
ad
a
d
ir
ec
ti
o
n
o
f
ef
fe
ct
in
th
e
re
p
li
ca
ti
o
n
sa
m
p
le
s
co
n
si
st
en
t
w
it
h
th
e
d
is
co
v
er
y
sa
m
p
le
s
an
d
5
d
id
n
o
t.
F
o
r
m
en
o
p
au
se
,
1
5
w
er
e
co
n
si
st
en
t
an
d
1
w
as
n
o
t.
Human Molecular Genetics, 2014, Vol. 23, No. 9 2493
phenotypes from GWAS scans, e.g. type 1 diabetes, multiple
sclerosis and lupus (http://www.genome.gov/gwastudies/).
This would be a good candidate to follow-up in additional
cohorts with menarche data and if substantiated would provide
evidence for an immunological pathway involved in both pheno-
types. Despite finding no individual locus associated with both
age at menarche and age at menopause, the positive although
modest genetic correlation (rgenetic ¼ 0.138) suggests that
common genetic loci do exist, likely with very subtle effects.
Our pathway analysis also suggests that there be one or two path-
ways of shared aetiology between the two traits, with many
others uniquely involved.
Future studies could include increasing the sample size in the
discovery meta-analysis or replication of the top signals in add-
itional cohorts. This is important since most of our participating
studies were Caucasian, therefore other ethnic groups need to be
similarly analysed. Studies are ongoing which include indivi-
duals of multiple ethnicities, which should narrow down the as-
sociation further. Also, other than adjusting for birth year in
menarche analysis, we did not correct for environmental
factors which may influence reproductive life span (such as
early obesity or adult-age smoking). A further limitation of our
study is that the cohorts included in the analysis were predomin-
antly the same as those used in the meta-analyses for the individ-
ual traits (2,3). Thus, finding that four of the six top hits for
reproductive lifespan had been reported previously for one of
the individual traits, was not necessarily surprising, as these
had very low P values in the original analysis. One of the limita-
tions of the bivariate meta-analysis is that very strong signals in
individual traits can drive the bivariate statistic over the P, 5 ×
10-8 threshold. The method is therefore best applied to signals
that are sub-genome-wide significant in individual traits, or to
use in pathway analyses than can highlight biological processes
common to both traits.
We identified a novel variant associated with age at natural
menopause which is a synonymous exonic SNP in the MSH6
gene on chromosome 2. The SNP had a minor allele frequency
of 18% and the rare allele increased menopause age by 1.3
months per allele. MSH6 heterodimerizes with MSH2 to form
the MutS alpha protein complex, which is involved in mismatch
repair (MMR), predominantly of single base mismatches and
small dinucleotide insertion/deletion loops (20). It forms a
complex with MutL alpha which is a heterodimer of PMS1
and MLH1. Germline mutations in MSH6, MSH2 and MLH1
have been associated with hereditary non-polyposis colorectal
cancer (HNPCC) (21). MSH6 mutations are rarer than mutations
in the other two genes, being found in 10–20% of HNPCC cases,
who often have an atypical presentation and increased predispos-
ition to endometrial cancer (22,23). No role for MSH6 in repro-
ductive ageing has been described previously, but other genes
Figure 1.Regional plot illustrating the strength of association (2log10 P) versus hg19 position. The purple diamond represents the lead SNP in the combined analysis
of replication and discovery data. Other dots, coloured according to the degree of pairwise linkage disequilibrium, represent single SNP test statistics for discovery
stage only, including rs1800932, which was the SNP with lowest P value in the discovery analysis. The lower panels show structures of genes; layered ENCODE
histone modification marks (H3K4Me1 which marks enhancers; H3K4Me3 which marks promoters and H3K27Ac which marks active regulatory regions) and
linkage disequilibrium pairwise correlation (r2) derived from the CEU population in the 1000 Genomes Project, where white corresponds to r2 ¼ 0 and black to
r2 ¼ 1.
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involved in DNA repair were identified in the recent GWAS for
age at menopause, including EXO1, UIMC1, MCM8 and
POLG(3). EXO1 has 5′ –3′ exonuclease activity and interacts
with several of the MMR proteins, including MSH2, MLH1,
MSH3, PCNA and WRN for its role in MMR and recombination
(24). UIMC1 recruits BRCA1 to DNA damage sites and initiates
G2/M checkpoint control (25). MCM8 is a member of a family of
DNA replication complex proteins and is thought to have a role
in meiotic double-strand break repair (26). Finally, POLG is re-
sponsible for the replication and repair of the mitochondrial
genome (27). Thus, variation in DNA repair processes, including
single nucleotide, double-strand and mitochondrial DNA repair,
appear to play a crucial role in determining age at natural meno-
pause. A recent paper showed accumulation of double-strand
DNA breaks in human follicles with age, with concomitant
downregulation of key DNA repair genes BRCA1, MRE11,
Rad51 and ATM, providing evidence that these processes play
a functional role in ovarian ageing (28). It has also been reported
that carriers of germline mutations in MMR genes, namely
BRCA1 and BRCA2 are at increased risk of early menopause
(29–32). We demonstrated that rs1800932 is an expression
quantitative trait locus for MSH6, with the rarer allele being asso-
ciated with increased levels of mRNA. Thus, the lower expres-
sion of MSH6 is associated with earlier menopause, consistent
with the work of Titus et al. (28), where downregulation of
DNA repair genes was associated with ovarian ageing. The
effect of the MSH6 variant on menopause age is relatively
small and only explains a small proportion of the variance in
menopause age. There are thus likely to be many more undiscov-
ered genetic variants responsible for determining age at natural
menopause.
The mechanism by which DNA repair influences timing of
menopause is yet to be determined, but it is conceivable that
damage to DNA of meiotic cells, if not repaired effectively,
would result in the activation of apoptotic pathways to prevent
transmission of potentially deleterious mutations to offspring.
It is known that in non-meiotic cells DNA damage results in
increased apoptosis and thus it is conceivable that similar pro-
cesses affect germ cells. Mouse models of the BRCA1 MMR
gene have marked depletion of germ cells (33). Oocytes are
lost throughout female life until menopause, predominantly by
apoptosis. Any increase in apoptosis would therefore be
expected to exhaust the oocyte pool prematurely and result in
earlier menopause. We have described a novel association
between a key DNA MMR gene and age at menopause, implicat-
ing MMR as a key process involved in determining reproductive
lifespan.
MATERIALS AND METHODS
Estimation of genetic correlation between menarche
and menopause
We used our largest individual study the Women’s Genome
Health Study (WGHS) (total sample N ¼ 23 294) to test for
genome-wide genetic correlation between timing of menarche
and menopause. The total joint contribution of common SNPs
to both age of menarche and age of menopause in the WGHS
was estimated using the REML method implemented in
GCTA (18,19). The genetic-related matrix in the WGHS was
calculated using 329 966 autosomal SNPs with minor allele fre-
quency .0.01. For analysis of the joint heritability, this matrix
was pruned to include only women with relatedness estimate
,0.025, leaving a total of 21 505 individuals with age of menar-
che and 11 025 with age at natural menopause.
GWA studies for menarche and menopause
Full details of the individual GWAS can be found in the original
publications, but briefly: the menarche GWAS included 32
studies, comprising 87 802 women and the menopause GWAS
included 22 studies, comprising 38 968 women: all were of
White European ancestry. Nineteen studies were included in
both GWAS meta-analyses, although the number of women
from each study differed (N ¼ 71 942 for menarche and N ¼ 33
460 for menopause). Women with recalled age at menarche
between 9 and 17 years were included in the analysis. Age at
natural menopause was defined as the age at the last menstrual
period that occurred naturally between the ages of 40 and 60
years. Women were excluded with menopause due to hysterec-
tomy and/or bilateral ovariectomy, or chemotherapy/irradiation,
if validated by medical records, and women using HRT before
menopause. All studies were approved by local ethics committees
and all participants provided written informed consent. Each study
performed genome-wide association testing for age at menarche or
menopause across 2.5 million imputed SNPs, based on linear re-
gression under an additive genetic model. Individual study data
were meta-analysed using the METAL software package;
genomic control (GC) adjustments were applied. We considered
P-values of ,5 × 1028 to indicate genome-wide significance.
Discovery bivariate GWAS meta-analysis
We performed multi-phenotype GWAS meta-analyses with ag-
gregate data (Z test statistics) from each univariate GWAS
meta-analysis (inverse-variance meta-analysis with GC con-
trols, as described above) of age at menarche and natural
menopause using our newly developed algorithm, empirical-
weighted linear-combined test statistics (eLC) (34,35).
Briefly, eLC directly combined correlated test statistics
obtained from univariate GWAS meta-analyses with a
weighted sum of univariate test statistics to empirically maxi-
mize the overall association signals and also to account for
the phenotypic correlation between menarche and menopause.
Our eLC approach is expressed as
SeLC =
∑k
1
[max(|Tk |, c)∗|Tk|]
where c is some given non-negative constant. The weight in this
new test statistics will be optimally determined by the specific
data structure. For instance, when c ¼ 0, the test statistics
simply reduces into sum of squares of Tk. When c is relatively
large, equal weight is assigned to each Tk. Ideally, we would
like to find an optimal value of c, so the SeLC performs as a
linear combination of Ti when under the H0; but, under the alter-
native HA, more weight is given to the larger true Ti. The bona-
fide P-value for SeLC then can be estimated by applying
permutation or perturbation techniques. The variance–
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covariance matrix S of univariate test statistics using the
sample covariance matrix of the test statistics of all SNPs
from univariate GWAS analyses as an approximation. S:
Var(Z1) Cov(Z1, Z2)
Cov(Z1, Z2) Var(Z2)
[ ]
where Z1 consists of unbiased univariate test statistics of all the
SNPs for the first trait on genome-wide scale, so does Z2. On the
other hand, S can be estimated by using generalized least
squares from individual-level data. Bivariate P-values of
,5 × 1028 were considered genome-wide significant with po-
tential pleiotropic effects, except when one of the individual
trait P values was lower than the bivariate P value. The
eLC method is implemented in eLX package using C++ and
is available at https://sites.google.com/site/multivariateyih-
sianghsu/.
Replication strategy
All SNPs with a P value of ,1 × 1027 in the bivariate analysis
were taken forward for replication in 22 additional cohorts with
in silico data, which included data from the iCOGs
meta-analysis, which incorporated 16 individual studies. We
also determined for each SNP whether any SNPs in LD with
the lead SNP (,1 Mb away and r2 . 0.8) were more strongly
associated with each of the traits in the individual menarche or
menopause GWAS studies. There were 10 proxy SNPs with a
lower P value in the individual trait and these were also taken
forward for in silico replication. Therefore, in total 16 SNPs
were tested in replication cohorts (Supplementary Material,
Table S1).
Access to data is available via the GREAT database https://
ifar-great.hsl.harvard.edu/ or by contacting the authors directly.
eQTL analysis
The novel genome-wide associated SNP for age at menopause
(rs1800932) and SNPs in LD with this SNP (r2. 0.9) were
searched against a multi-tissue eQTL database of expression
of SNP results (3). In four of the tissues [monocytes (36),
blood (37), lung (38) and liver (39)] there was an eQTL for
MSH6 and for three of these (monocytes, blood and liver) the
SNP most strongly associated with expression of MSH6 was
our top GWAS SNP or one in strong LD with it (r2. 0.95).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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